Belgrade, United States
Bacterin International Holdings is a leading medical device company and accredited tissue bank that specializes in the design, processing, manufacturing, and marketing of advanced medical products. The company places a strong emphasis on patient safety and surgical ease, ensuring that its products cater to specific niche needs within the healthcare industry.
The Biologics Division at Bacterin International Holdings has made significant advancements in enhancing the handling characteristics of allograft bone while retaining numerous benefits inherent in autograft bone. Notably, its OsteoSponge® product line features a highly osteoconductive matrix essential for neovascularization and bone formation and exhibits osteoinductive properties by exposing native BMP’s and growth factors. Additionally, Bacterin Biologics offers an allograft portfolio tailored to meet the specific needs of the Spine, Cranio-maxillofacial, reconstructive, and trauma markets.
Founded in 1998, the company operates within the Biotechnology and Manufacturing industries. The last recorded investment was a $4.00M Post-IPO Debt investment on 10th March 2014.
